diabetics
Cancer Drug Gleevec May Treat Type 1 Diabetes
Filed in archive Research , Treatment by Gloria Gamat on November 19, 2008
Cancer Drug Gleevec May Treat Type 1 Diabetes
Experiments with mice by researchers at the University of California San Francisco (UCSF) found that the popular cancer drug Gleevec (and a similar drug called Sutent) may prevent the onset of type 1 diabetes.

According to lead researcher Jeffrey Bluestone, director of the Diabetes Center at the University of California, San Francisco:

"Although targeted to the Bcr-Abl kinase, Gleevec has been shown to affect related kinases including platelet-derived growth factor potentially involved in various cell types critical to the development and progression of autoimmune diseases such as type 1 diabetes.

The study shows that this class of drugs could prevent and reverse diabetes in a mouse model of type 1 diabetes. Moreover, a significant percentage of the animals remain in long-term remission even after discontinuation of the therapy."


Findings were published in this week's online issue of the Proceedings of the National Academy of Sciences (PNAS).

Gleevec is known for use in the treatment of leukemia and other cancer types.

Permalink: Cancer Drug Gleevec May Treat Type 1 Diabetes
Tags: type  1  diabetes  Gleevec  2008  type+diabetes  cancer+drug  drug+gleevec 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/138249
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Cancer Drug Gleevec May Treat Type 1 Diabetes:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 4 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!